Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era.
Eric V LiAnna M BuszaMohammad R SiddiquiJonathan A AguiarMary-Kate KeeterClayton NeillSai K S R KumarXinlei MiEdward M SchaefferHiten D PatelAshley Evan RossPublished in: Prostate cancer and prostatic diseases (2024)
The subsequent detection rate of csPCa among patients not initially biopsied after mpMRI was low at 2.4%. Decisions to omit biopsy after initial reassuring PHI, PSAD, and mpMRI appear safe with subsequent reassuring serum biomarkers and for cause mpMRI during follow-up.